These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25561511)

  • 1. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
    Kopetz S; Tabernero J; Rosenberg R; Jiang ZQ; Moreno V; Bachleitner-Hofmann T; Lanza G; Stork-Sloots L; Maru D; Simon I; Capellà G; Salazar R
    Oncologist; 2015 Feb; 20(2):127-33. PubMed ID: 25561511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
    Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
    Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 4. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
    Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
    Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers.
    Fu T; Pappou EP; Guzzetta AA; Calmon Mde F; Sun L; Herrera A; Li F; Wolfgang CL; Baylin SB; Iacobuzio-Donahue CA; Tong W; Ahuja N
    Ann Surg; 2016 Feb; 263(2):337-44. PubMed ID: 25822686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
    Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
    Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
    Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
    Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
    Woodard GA; Gubens MA; Jahan TM; Jones KD; Kukreja J; Theodore PR; Cardozo S; Jew G; Clary-Macy C; Jablons DM; Mann MJ
    Clin Lung Cancer; 2014 Nov; 15(6):426-32. PubMed ID: 25258195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells.
    Lloyd JM; McIver CM; Stephenson SA; Hewett PJ; Rieger N; Hardingham JE
    Clin Cancer Res; 2006 Jan; 12(2):417-23. PubMed ID: 16428481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
    Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
    Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors.
    Kang SI; Kim DW; Kwak Y; Lee HS; Kim MH; Kim MJ; Oh HK; Kang SB
    Int J Colorectal Dis; 2018 Jun; 33(6):719-726. PubMed ID: 29594445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
    Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
    J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients.
    Sveen A; Ågesen TH; Nesbakken A; Meling GI; Rognum TO; Liestøl K; Skotheim RI; Lothe RA
    Clin Cancer Res; 2012 Nov; 18(21):6001-10. PubMed ID: 22991413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.